Form D · Biotechnology
Otolith Sound, Inc.
Washington, DC · CIK 0001677664
Offering snapshot reported Oct 9, 2024 · SEC filing
- Reported sold
- $4.9M Offering amount: $8.92M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 29, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 9, 2024 | Initial | $4,899,055 | No comparison | 3 | SEC filing |
| Feb 7, 2023 | Initial | $24,799,853 | No comparison | 33 | SEC filing |
| Nov 28, 2018 | Initial | $750,000 | No comparison | 11 | SEC filing |
| Apr 13, 2018 | Initial | $405,000 | No comparison | 4 | SEC filing |
| Jun 21, 2016 | Initial | $25,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-526231
Source: Form D, filed Oct 9, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anthony Aiudi | Director |
| Jon Akers | Executive |
| John Daggitt | Executive |
| Didier Depireux | Executive |
| Kevin Franck | Executive |
| Tom Hardart | Executive |
| Thomas Hardart | Executive |
| Raphael Michel | Director |
| Samuel Owen | Director, Executive |
| Dan Wagner | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Massachusetts Ave Nw, Fl7
Washington, DC, 20001
Washington, DC, 20001